This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

John Desjarlais, PhD
Chief Scientific Officer at Xencor, Inc.
Speaker

Profile

John Desjarlais is the Chief Scientific Officer of Xencor, where he and his team have built a variety of antibody engineering and enhancement platforms, leading to multiple clinical-stage and approved antibody programs. Prior to Xencor, John was an Assistant Professor of Chemistry at Penn State University. His education includes a Postdoctoral Fellowship at UC Berkeley, a PhD in Biophysics from Johns Hopkins University, and a BS in Physics from UMass Amherst.

Agenda Sessions

  • Bispecific Antibodies for Oncology and Autoimmune Diseases

    11:30am
  • Chairman’s Remarks - Antibody-Based Approaches to Treat Autoimmunity

    2:25pm